Clinical repercussions of analytical interferences due to aldosterone antagonists in digoxin immunoassays: An assessment

Therapeutic Drug Monitoring

Volumn 32, Issue 2, 2010, Pages 169-176

  Cobo, Ana ^a   Martín Suarez, Ana ^a   Calvo, Maria Victoria ^a,b   Domínguez Gil, Alfonso ^a,b   De Gatta, Maria Mar Fernández ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Clinical repercussions; Cross reactivity; Digoxin immunoassays; Spironolactone; Therapeutic drug monitoring

Indexed keywords

CANRENOATE POTASSIUM; DIGOXIN; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CROSS REACTION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FALSE POSITIVE RESULT; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ULTRAFILTRATION; BLOOD; CHEMICAL ANALYSIS; COMPARATIVE STUDY; DRUG INTERACTION; IMMUNOASSAY; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; STANDARDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHEMISTRY TECHNIQUES, ANALYTICAL; DIGOXIN; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS;

EID: 77950260142     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181cdc93e     Document Type: Article

References (18)

1. Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Clinical benefits of low serum digoxin concentrations in heart failure. JAm Coll Cardiol. 2002;39: 946-953.
2. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003; 289:871-878.
3. Ahmed A, Pitt B, Shahbundin H, et al. Effects of digoxin at low serum digoxin concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol. 2008;123: 138-146.
4. Vivo RP, Krim SR, Perez J. Digoxin: current use and approach to toxicity. Am J Med Sci. 2008;336:423-428.
5. Okazaki M, Tanigawara Y, Kita T, et al. Cross reactivity of TDX and OPUS immunoassay system for serum digoxin determination. Ther Drug Monit. 1997;19:657-662.
6. Steimer W, Muller C, Eber B. Digoxin assays: frequent, substantial and potentially dangerous interference by spironolactone, canrenone and other steroids. Clin Chem. 2002;48:507-516.
7. Dasgupta A, Saffer H, Wells A, et al. Bidirectional (positive/negative) interference of spironolactone, canrenone and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin. J Clin Lab Anal. 2002;16:172-177.
8. Dasgupta A, Tso G, Wells A. Effects of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay. Ther Drug Monit. 2008;30:744-747
9. Bauman JL, DiDomenico RJ, Viana M, et al. A method of determining the dose of digoxin for heart failure in the modern era. Arch intern Med. 2006; 166:2539-2545.
10. Fraser CG. Desirable standards of performance for therapeutic drug monitoring. Clin Chem. 1987;33:387-389.
11. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
12. Jones TE, Morris RG. Discordant results from "real world" patients samples assayed for digoxin. Ann Pharmacother. 2008;42:1797-1803.
13. Mart́in-Suárez A, Calvo MV, Morales AI, et al. Minimizing digoxin-like immunoreactivity with TDx digoxin in dialysis patients. Ther Drug Monit. 1997;19:364-365.
14. Calvo MV, Martin-Suarez A, Martin Luengo C, et al. Interaction between digoxin and propafenone. Ther Drug Monit. 1989;11:10-15.
15. Miller JJ, Valdes R. Approaches to minimizing interference by cross-reacting molecules in immunoassays. Clin Chem. 1991;37:144-153.
16. Dasgupta A. Endogenous and exogenous digoxin-like immunoreactive substances. Impact on therapeutic drug monitoring of digoxin. Am J Clin Pathol. 2002;118:132-140.
17. Zaera S, Hermida J, Tutor JC. Effect of analytical inaccuracy on dose adjustment for vancomycin, amikacin, and tobramycin using the Abbottbase® Pharmacokinetics System. Ther Drug Monit. 2002;24: 696-700.
18. Neef C, Touw DJ, Harteveld AR, et al. Pitfalls in TDM of antibiotic drug: analytical and modelling issues. Ther Drug Monit. 2006;28: 686-689.